TG 02 - Targovax

Drug Profile

TG 02 - Targovax

Alternative Names: TG02 - Targovax

Latest Information Update: 28 Oct 2016

Price : $50

At a glance

  • Originator Targovax
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Helper-inducer T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer
  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Colorectal cancer (Combination therapy, Recurrent) in Australia (Parenteral) (NCT02933944)
  • 01 Sep 2016 Phase-I clinical trials in Colorectal cancer (Monotherapy, Recurrent) in Australia (Parenteral) (NCT02933944)
  • 02 Jun 2016 Targovax receives approval to conduct a phase I trial in Colorectal cancer in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top